March 25, 2026-
VeonGen Therapeutics has reported encouraging early clinical progress for VG801, an investigational dual-AAV gene therapy designed to treat ABCA4-associated retinal diseases, including Stargardt disease. Updated findings from the ongoing Phase 1/2 first-in-human clinical trial (NCT07002398) indicate promising preliminary efficacy alongside a favorable safety profile.
The therapy is currently being evaluated in both adult and pediatric patients to assess safety, tolerability, and early signs of efficacy. As of the latest clinical update, nine patients have completed six months of follow-up, with several participants reaching twelve months after treatment. To date, VG801 has been well tolerated, with no dose-limiting toxicities or serious adverse events reported.
Preliminary efficacy data show consistent functional improvements in best-corrected visual acuity (BCVA) as well as in the Virtual Reality Visual Test (VRVT), a novel digital endpoint designed to evaluate functional vision in real-world scenarios. Importantly, these improvements have been sustained through both six- and twelve-month follow-up, suggesting durable therapeutic activity.
VG801 is a dual-AAV gene therapy platform developed to deliver a full-length functional copy of the ABCA4 gene, which is too large to fit into a single AAV vector. To overcome this challenge, VeonGen utilizes a two-vector AAV delivery strategy, enabling the therapeutic gene to be reassembled within retinal cells after delivery. The therapy also incorporates the company’s proprietary vgAAV capsid, designed to improve photoreceptor targeting and transduction efficiency.
The program has also received strong regulatory support. VG801 has been selected for the FDA Rare Disease Endpoint Advancement (RDEA) pilot program, which supports the development of novel endpoints for rare disease clinical trials. In this case, the Virtual Reality Visual Test (VRVT) is being developed as a potential functional vision endpoint for future pivotal studies. The therapy has also received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which allows enhanced regulatory interaction and may accelerate clinical development.
Regulatory clearances for the VG801 program extend globally. The therapy has received IND clearance from the U.S. FDA, Clinical Trial Authorization (CTA) from the European Medicines Agency, and IND approval from China’s Center for Drug Evaluation (CDE), allowing the program to advance internationally.
Clinical data from the ongoing trial will be presented in an oral presentation at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, highlighting VG801’s scientific and clinical progress within the field of ophthalmic gene therapy.
Stargardt disease is the most common inherited retinal dystrophy, affecting approximately 1 in 8,000 to 10,000 individuals worldwide. The disease is caused by mutations in the ABCA4 gene, which lead to progressive degeneration of retinal cells and gradual central vision loss, often beginning in childhood or adolescence. Currently, no approved therapies exist for Stargardt disease, making the development of innovative treatments such as AAV-based gene therapies particularly important.
If clinical development continues to show positive results, VG801 could represent a promising AAV gene therapy approach to address the underlying genetic cause of Stargardt disease and potentially restore functional vision for patients affected by this currently untreatable retinal disorder.
